SPN-812 Gains A Third Positive Study for the Treatment of Adolescents with ADHD

In its third Phase III study, SPN-812 met its primary endpoint with positive results. Marking a major step for Supernus Pharmaceuticals novel ADHD treatment.<br /> <br />